Last year, Bristol Myers Squibb devoted half a page of its annual report to its diversity, equity and inclusion efforts, ...

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...

Biogen Inc. (NASDAQ:BIIB – Get Free Report) saw some unusual options trading on Wednesday. Traders acquired 6,024 call ...

Evercore ISI analyst Umer Raffat maintained a Buy rating on Biogen (BIIB – Research Report) yesterday. The company’s shares closed yesterday at ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

EPS and revenue topped estimates, but analysts cite Medicare changes and MS declines as headwinds. Leqembi and Skyclarys remain key growth drivers.

Henry Gosebruch, Neumora’s CEO since 2023, will depart. Elsewhere, Biogen dropped two antisense drugs in a pipeline cull and Voyager hit a setback for its ALS gene therapy.

Q4 2024 Earnings Call Transcript February 12, 2025 Operator: Good morning. My name is Jennifer and I will be your conference ...

The company posted fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company reported sales ...

Mizuho Securities analyst Salim Syed maintained a Buy rating on Biogen (BIIB – Research Report) yesterday and set a price target of $207.00.

Good morning, Boston. Spring training has begun, and here are the five things you need to know, including Biogen cutbacks, CVS's new CEO, Eastern Nazarene sale, spring training, Rat Day, and more Vale ...